Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors

Pediatric Blood and Cancer

Volumn 61, Issue 1, 2014, Pages 145-150

  Norris, Robin E ^a,b   Adamson, Peter C ^b   Nguyen, Vu T ^b   Fox, Elizabeth ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Olaparib; PARP inhibitor

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FIRTECAN; IRINOTECAN; MELPHALAN; OLAPARIB; TOPOTECAN; VINCRISTINE; CAMPTOTHECIN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA CELL LINE; CELL LYSATE; CHILDHOOD CANCER; CLINICAL EVALUATION; CONTROLLED STUDY; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG SENSITIVITY; EWING SARCOMA CELL LINE; FEMALE; GROWTH INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MEDULLOBLASTOMA CELL LINE; MOUSE; NEUROBLASTOMA CELL LINE; NONHUMAN; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; RHABDOMYOSARCOMA CELL LINE; SOLID TUMOR; TUMOR XENOGRAFT; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER MODEL; DRUG EFFICACY; DRUG TOLERABILITY; EWING SARCOMA; HUMAN; HUMAN CELL; IC50; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOSARCOMA; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; NEOPLASMS; SCID MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, SCID; NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891693900     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24697     Document Type: Article

References (44)

1. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: Aproof-of-concept trial. Lancet 2010;376:245-251.
2. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010;376:235-244.
3. Pollack IF, Hamilton RL, Sobol RW, et al. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the Children's Oncology Group. Pediatr Blood Cancer 2010;55:1066-1071.
4. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor {alpha} and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 2010;28:1337-1344.
5. Staal FJ, de Ridder D, Szczepanski T, et al. Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype. Leukemia 2010;24:491-499.
6. Barton VN, Donson AM, Kleinschmidt-DeMasters BK, et al. PARP1 expression in pediatric central nervous system tumors. Pediatr Blood Cancer 2009;53:1227-1230.
7. Wagner LM, McLendon RE, Yoon KJ, et al. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin Cancer Res 2007;13:5418-5425.
8. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: Lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006;24:3799-3808.
9. Thomson B, Tritt R, Davis M, et al. Histology-specific expression of a DNA repair protein in pediatric rhabdomyosarcomas. J Pediatr Hematol Oncol 2001;23:234-239.
10. Phillips CL, Gerbing R, Alonzo T, et al.MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 2010;55:248-253.
11. Shang X, Vasudevan SA, Yu Y, et al. Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma. Oncogene 2010;29:4938-4946.
12. Tabori U, Baskin B, Shago M, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010;28:1345-1350.
13. Cattelani S, Defferrari R, Marsilio S, et al. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: Results of a pilot study on 239 patients. Clin Cancer Res 2008;14:3248-3253.
14. Strahm B, Malkin D. Hereditary cancer predisposition in children: Genetic basis and clinical implications. Int J Cancer 2006;119:2001-2006.
15. Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6:945-956.
16. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG 1436 1. J Natl Cancer Inst 2004;96:56-67.
17. Daniel RA, Rozanska AL, Mulligan EA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-01499. Br J Cancer 2010;103:1588-1596.
18. Daniel RA, Rozanska AL, Thomas HD, et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 2009;15:1241-1249.
19. Horton TM, Jenkins G, Pati D, et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: Influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009;8:2232-2242.
20. Cheng CL, Johnson SP, Keir ST, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005;4:1364-1368.
21. Ossovskaya V, Li L, Broude E, et al. BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer. [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5552.
22. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13:1383-1388.
23. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192-1200.
24. Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): A comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008;111:1078-1084.
25. Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD 2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009;27:15s (suppl; abstr 5500).
26. Fong PC, Boss DS, Carden CP, et al. AZD 2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. J Clin Oncol 2008;26:15s (suppl; abstr 5510).
27. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009;27:18s (suppl; abstr CRA501).
28. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-134.
29. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113: 1875-1891.
30. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-2519.
31. Chuang HC, Kapuriya N, Kulp SK, et al. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012; 134:649-659.
32. Scribner DR, Jr., Benbrook DM. Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecol Oncol 2002;85:223-225.
33. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72:5588-5599.
34. Sandhu S, Wenham R, Wilding G, et al. First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. J Clin Oncol 2010;28:15s (suppl; abstr 3001)
35. Mosse YP, Greshock J, Margolin A, et al. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 2005;43:390-403.
36. Huang HJ, Angelo LS, Rodon J, et al. R 1507 an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: Convergence at the IGF/IGFR/Akt axis. PLoS ONE 2011;6:e26060.
37. Norris RE, Minturn JE, Brodeur GM, et al. Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. Cancer Chemother Pharmacol 2011;68:1469-1475.
38. Norris RE, Rappaport EF, Adamson PC. Preclinical evaluation of pemetrexed in pediatric solid tumors. Pediatr Blood cancer 2011;57:1233-1235.
39. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
40. Kirstein MN, Houghton PJ, Cheshire PJ, et al. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 2001;7:358-366.
41. Pisano C, Vesci L, Fodera R, et al. Antitumor activity of the combination of synthetic retinoid ST 1926 and cisplatin in ovarian carcinoma models. Ann Oncol 2007;18:1500-1505.
42. Arrieta O, Gonzalez-De la Rosa CH, Arechaga-Ocampo E, et al. Randomized phase II trial of All-transretinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3463-3471.
43. Goncalves A, Camerlo J, Bun H, et al. Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: Clinical results and pharmacokinetics. Anticancer Res 2001;21:1431-1437.
44. Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 2013;31:1592-1605.